Supplementary Materials

Supplementary Material for:

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

Renier J. Brentjens,* Marco L. Davila, Isabelle Riviere, Jae Park, Xiuyan Wang, Lindsay G. Cowell, Shirley Bartido, Jolanta Stefanski, Clare Taylor, Malgorzata Olszewska, Oriana Borquez-Ojeda, Jinrong Qu, Teresa Wasielewska, Qing He, Yvette Bernal, Ivelise V. Rijo, Cyrus Hedvat, Rachel Kobos, Kevin Curran, Peter Steinherz, Joseph Jurcic, Todd Rosenblat, Peter Maslak, Mark Frattini, Michel Sadelain*

*Corresponding author. E-mail: brentjer@mskcc.org (R.B.); m-sadelain@ski.mskcc.org (M.S.)

Published 20 March 2013, Sci. Transl. Med. 5, 177ra38 (2013)
DOI: 10.1126/scitranslmed.3005930

This PDF file includes:

  • Fig. S1. Trial schema for adult patients with relapsed B-ALL.
  • Fig. S2. Trial schema for adult patients with B-ALL in CR.
  • Fig. S3. Serum cytokine detection and correlation with tumor burden.
  • Fig. S4. Rapid hematopoietic recovery in MSK-ALL05 after infusion with 19-28z T cells.
  • Table S1. Characteristics of infused 19-28z CAR-transduced T cells; tumor burden in apheresis and BM.
  • Table S2. Adverse events.
  • Table S3. Percentage of 19-28z CAR+ T cells detected in the CD3+ T cells of the peripheral blood and of the BM (in parenthesis) of patients up to 57 days after CAR-modified T cell therapy.

[Download PDF]